• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    IDEXX Releases 2024 Corporate Responsibility Report, Highlighting Progress Against Its Goals

    7/30/25 7:00:00 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $IDXX alert in real time by email

    WESTBROOK, Maine, July 30, 2025 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today released its 2024 Corporate Responsibility Report "Enhancing the health and well-being of pets, people, and livestock" highlighting progress toward goals closely aligned with its Purpose and business strategy.

    IDEXX Laboratories, Inc.

    The Care We Advance

    IDEXX brings clarity to the complex world of veterinary medicine through innovative diagnostic and software solutions. Key highlights from the report include the following:

    • Significantly advanced our innovation strategy in 2024, supporting the launch of the IDEXX inVue Dx™ Cellular Analyzer, a groundbreaking slide-free, real-time cellular imaging platform, and exited 2024 with eight additional new products and services launched or ready to launch.



    • Revolutionized cancer care by launching IDEXX Cancer Dx™ testing in North America in March 2025, a first-of-its-kind diagnostic panel, addressing a critical need for early cancer detection, starting with canine lymphoma, and planning to expand IDEXX Cancer Dx testing over the next three years to cover the majority of canine cancer cases.



    • Supported underserved communities by enabling access to care for over 79,000 animals in 2024, with a cumulative total of over 704,000 animals through our global social initiatives since 2022.



    • Provided the equivalent of approximately $5.5 million in continuing education credit offerings to veterinary professionals in 2024.

    The People We Support

    IDEXX strives to create a collaborative and inclusive culture that embraces everyone's unique perspectives, talents, and experiences. Key highlights from the report include the following:

    • Logged over 86,000 hours of learning and development, including 23,200 hours of STEM and AI learning.



    • Supported achieving over 25,000 self-reported employee volunteer hours, exceeding our 2025 goal of 15,000 annual volunteer hours.



    • Achieved a favorable engagement rate of 80% on our annual employee engagement survey.

    The Planet We Share

    IDEXX recognizes the importance of protecting the planet and its relationship to animal and human health. Key highlights from the report include the following:

    • Signed three virtual power purchase agreements to add new, clean electricity to the North American and European energy grids.



    • Added more electric and hybrid vehicles to our commercial fleet, which is composed of over 35% electric and hybrid models.



    • Advanced global product circularity in 2024 by servicing over 34,000 instruments and completing over 90,000 point-of-service upgrades on select IDEXX instruments.

    "We made steady progress in 2024, advancing our corporate responsibility goals and fulfilling our commitments across our pillars—The Care We Advance, The People We Support, and The Planet We Share," said Jay Mazelsky, IDEXX President and Chief Executive Officer. "I remain proud of how IDEXX amplifies our Purpose through our corporate responsibility initiatives, which all support and are aligned with our long-term business strategy."

    IDEXX's 2024 report covers corporate responsibility topics that we believe are most relevant to our Purpose and stakeholders. We use well-established reporting standards that are aligned with frameworks, such as those released by the Sustainability Accounting Standards Board and the Task Force on Climate-Related Disclosures. Read the 2024 Corporate Responsibility Report here.

    About IDEXX

    IDEXX Laboratories, Inc., is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500® Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit: www.idexx.com.

    Note Regarding Forward-Looking Statements

    This news release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "expects," "may," "anticipates," "intends," "would," "will," "plans," "believes," "estimates," "should," "project," and similar words and expressions. These forward-looking statements are intended to provide our current expectations or forecasts of future events; are based on current estimates, projections, beliefs, and assumptions; and are not guarantees of future performance. Actual events or results may differ materially from those described in the forward-looking statements. These statements are subject to risks, uncertainties, assumptions, and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by IDEXX pursuant to United States securities laws contain discussions of some of these risks and uncertainties. IDEXX assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers are advised to review IDEXX's filings with the United States Securities and Exchange Commission (which are available from the SEC's EDGAR database at sec.gov and via IDEXX's website at idexx.com).

    IDEXX Logo (PRNewsfoto/Idexx Laboratories, Inc.)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/idexx-releases-2024-corporate-responsibility-report-highlighting-progress-against-its-goals-302515322.html

    SOURCE IDEXX Laboratories, Inc.

    Get the next $IDXX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IDXX

    DatePrice TargetRatingAnalyst
    8/5/2025$545.00 → $785.00Buy
    BTIG Research
    7/1/2025$625.00Buy
    Jefferies
    12/2/2024$500.00Outperform
    Leerink Partners
    7/25/2024$580.00Buy
    BTIG Research
    1/30/2024$525.00Overweight → Neutral
    Piper Sandler
    12/7/2023$602.00Outperform
    Exane BNP Paribas
    12/4/2023Neutral → Buy
    Cleveland Research
    8/2/2023$610.00Overweight → Neutral
    Atlantic Equities
    More analyst ratings

    $IDXX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IDEXX Laboratories Announces Second Quarter Results

    Achieves second quarter revenue growth of 11% as reported and 9% organic, supported by CAG Diagnostics recurring revenue growth of 9% as reported and 7% organic. Advances IDEXX's innovation agenda and continues strong global commercial execution, resulting in record quarterly instrument placements, including nearly 2,400 IDEXX inVue Dx™ placements. Delivers EPS of $3.63, an increase of 49% as reported, and 17% on a comparable basis, net of $0.56 EPS growth benefit from comparison to prior year period discrete litigation expense accrual, and including $0.07 benefit from a discrete tax reserve release. Increases 2025 revenue guidance to $4,205 million - $4,280 million, an increas

    8/4/25 6:30:00 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    IDEXX Releases 2024 Corporate Responsibility Report, Highlighting Progress Against Its Goals

    WESTBROOK, Maine, July 30, 2025 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today released its 2024 Corporate Responsibility Report "Enhancing the health and well-being of pets, people, and livestock" highlighting progress toward goals closely aligned with its Purpose and business strategy. The Care We AdvanceIDEXX brings clarity to the complex world of veterinary medicine through innovative diagnostic and software solutions. Key highlights from the report include the following: Significantly advanced our innovation str

    7/30/25 7:00:00 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    IDEXX Laboratories Elects Joseph L. (Jay) Hooley to Board of Directors

    IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the election of Joseph L. (Jay) Hooley to the Company's Board of Directors, effective July 10, 2025. "We are excited to welcome Jay to the IDEXX Board of Directors," said Lawrence D. Kingsley, the Company's Independent Non-Executive Board Chair. "Jay is an accomplished executive who brings extensive strategic thinking and financial leadership experience, along with investor perspective, from his tenure leading State Street during a period of global growth and technological transformation. Given his substantial public company board and corporate governance experience and his unique backgro

    7/10/25 7:00:00 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $IDXX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $IDXX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Executive Vice President Erickson Michael G sold $263,813 worth of shares (406 units at $649.96), decreasing direct ownership by 3% to 11,287 units (SEC Form 4)

    4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)

    8/14/25 6:01:09 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form 5 filed by Erickson Michael G

    5/A - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)

    8/14/25 6:00:34 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: New insider Erickson Michael G claimed ownership of 9,377 shares (SEC Form 3)

    3/A - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)

    8/14/25 6:00:06 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    BTIG Research reiterated coverage on IDEXX Labs with a new price target

    BTIG Research reiterated coverage of IDEXX Labs with a rating of Buy and set a new price target of $785.00 from $545.00 previously

    8/5/25 10:21:27 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Jefferies initiated coverage on IDEXX Labs with a new price target

    Jefferies initiated coverage of IDEXX Labs with a rating of Buy and set a new price target of $625.00

    7/1/25 8:38:56 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Leerink Partners initiated coverage on IDEXX Labs with a new price target

    Leerink Partners initiated coverage of IDEXX Labs with a rating of Outperform and set a new price target of $500.00

    12/2/24 6:57:33 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $IDXX
    SEC Filings

    View All

    SEC Form 10-Q filed by IDEXX Laboratories Inc.

    10-Q - IDEXX LABORATORIES INC /DE (0000874716) (Filer)

    8/4/25 4:22:36 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    IDEXX Laboratories Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - IDEXX LABORATORIES INC /DE (0000874716) (Filer)

    8/4/25 6:30:59 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    IDEXX Laboratories Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - IDEXX LABORATORIES INC /DE (0000874716) (Filer)

    7/10/25 7:00:41 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $IDXX
    Leadership Updates

    Live Leadership Updates

    View All

    IDEXX Laboratories Elects Joseph L. (Jay) Hooley to Board of Directors

    IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the election of Joseph L. (Jay) Hooley to the Company's Board of Directors, effective July 10, 2025. "We are excited to welcome Jay to the IDEXX Board of Directors," said Lawrence D. Kingsley, the Company's Independent Non-Executive Board Chair. "Jay is an accomplished executive who brings extensive strategic thinking and financial leadership experience, along with investor perspective, from his tenure leading State Street during a period of global growth and technological transformation. Given his substantial public company board and corporate governance experience and his unique backgro

    7/10/25 7:00:00 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    First Watch Announces Appointment of Irene Chang Britt to Board of Directors

    BRADENTON, Fla., July 19, 2023 (GLOBE NEWSWIRE) -- First Watch Restaurant Group, Inc. (NASDAQ:FWRG) ("First Watch" or the "Company"), the leading Daytime Dining concept serving breakfast, brunch and lunch, today announced the appointment of Irene Chang Britt to its Board of Directors, effective immediately. Ms. Chang Britt is an experienced independent board director and former Fortune 500 C-suite executive, who currently serves on the boards of established businesses and start-up companies representing a variety of industries, including retail, CPG, e-commerce and lifestyle. "We are thrilled to welcome Irene to the Board of Directors of First Watch, and I'm confident that our company wil

    7/19/23 4:15:00 PM ET
    $BHF
    $FWRG
    $IDXX
    Life Insurance
    Finance
    Restaurants
    Consumer Discretionary

    Ocular Therapeutix™ Appoints Merilee Raines to Its Board of Directors

    Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Merilee Raines to the Company's Board of Directors effective September 20, 2021. "We are excited to welcome Merilee to our Board of Directors," said Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix. "Merilee brings a wealth of operational, financial, and business experience to our team. Having started as employee #11 at IDEXX, she helped to drive a multitude of innovative growth strategies and successfully scaled the business from sta

    9/22/21 8:00:00 AM ET
    $IDXX
    $OCUL
    $TMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    $IDXX
    Financials

    Live finance-specific insights

    View All

    IDEXX Laboratories Announces Second Quarter Results

    Achieves second quarter revenue growth of 11% as reported and 9% organic, supported by CAG Diagnostics recurring revenue growth of 9% as reported and 7% organic. Advances IDEXX's innovation agenda and continues strong global commercial execution, resulting in record quarterly instrument placements, including nearly 2,400 IDEXX inVue Dx™ placements. Delivers EPS of $3.63, an increase of 49% as reported, and 17% on a comparable basis, net of $0.56 EPS growth benefit from comparison to prior year period discrete litigation expense accrual, and including $0.07 benefit from a discrete tax reserve release. Increases 2025 revenue guidance to $4,205 million - $4,280 million, an increas

    8/4/25 6:30:00 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    IDEXX Laboratories to Release 2025 Second Quarter Financial Results

    IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 second quarter financial results for Monday, August 4, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. EDT on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q2 2025 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen

    6/24/25 1:00:00 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    IDEXX Laboratories Announces First Quarter Results

    Achieves first quarter revenue growth of 4% as reported and 5% organic, supported by CAG Diagnostics recurring revenue growth of 3% as reported and 4.5% organic. Organic revenue growth supported by benefits from IDEXX execution drivers, including continued solid new business gains and strong year-over-year global premium instrument installed base growth, including over 300 IDEXX inVue Dx™ placements. Delivers EPS of $2.96, an increase of 5% as reported and 7% on a comparable basis, supported by gross margin expansion of 90 basis points as reported and 80 basis points on a comparable basis. Adjusts 2025 revenue guidance to $4,095 million - $4,210 million, an increase of $40 million

    5/1/25 6:30:00 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $IDXX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by IDEXX Laboratories Inc.

    SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)

    11/12/24 3:48:28 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by IDEXX Laboratories Inc.

    SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)

    11/4/24 11:47:05 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by IDEXX Laboratories Inc. (Amendment)

    SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)

    2/13/24 5:06:19 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care